trial to assess whether a reduced-dose regimen of apixaban (2.5 mg twice daily) would be noninferior to a full-dose regimen (5.0 mg twice daily) for the prevention of recurrent venous ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Participants were randomized to oral apixaban at a reduced dose (2.5 mg) or a full dose (5.0 mg) twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal ...

a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the API-CAT randomized trial showed. During 12 months of extended treatment after an initial 6 months or more of ...

One group received standard care, while the other got standard care plus apixaban (2.5 mg twice daily) for three months. After three months, the apixaban group had fewer clot recurrences—24% ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.